Powered by

DNARx Awarded DARPA Contract for up to $10.7 Million to Develop Non-Viral DNA-Encoded Gene Therapy to Protect Against Pandemic Influenza

Aug 06, 2019 - GlobeNewswire

DNARx's proprietary HEDGES„¢ non-viral gene therapy delivery platform promises rapid, reliable, low-cost and relatively simple manufacturing and delivery of gene vectors to treat a wide range of diseases, particularly as compared to currently-employed delivery of genes using viruses

SAN FRANCISCO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- DNARx, the developer of the pioneering HEDGES„¢, non-viral gene therapy delivery platform, announced today that the Defense Advanced Research Projects Ag...